Momenta Pharmaceuticals (NASDAQ:MNTA) Rating Increased to Buy at BidaskClub

Momenta Pharmaceuticals (NASDAQ:MNTA) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Tuesday, January 9th.

MNTA has been the topic of a number of other research reports. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Cowen set a $15.00 price target on shares of Momenta Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, November 1st. Robert W. Baird cut shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price target for the company from $22.00 to $15.00 in a research note on Friday, October 6th. ValuEngine cut shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Finally, JPMorgan Chase & Co. reissued a “hold” rating and issued a $14.00 price target on shares of Momenta Pharmaceuticals in a research note on Thursday, October 5th. Two equities research analysts have rated the stock with a sell rating and ten have assigned a hold rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $15.30.

Shares of Momenta Pharmaceuticals (MNTA) opened at $15.90 on Tuesday. The company has a market cap of $1,210.00, a P/E ratio of -19.88 and a beta of 1.80. Momenta Pharmaceuticals has a one year low of $11.85 and a one year high of $19.60.

In other news, Director Elizabeth Stoner sold 16,264 shares of Momenta Pharmaceuticals stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $18.00, for a total transaction of $292,752.00. Following the transaction, the director now owns 32,440 shares in the company, valued at approximately $583,920. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Craig A. Wheeler sold 4,116 shares of Momenta Pharmaceuticals stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $13.35, for a total value of $54,948.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 65,769 shares of company stock worth $978,675. Insiders own 4.40% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. New York State Common Retirement Fund raised its holdings in Momenta Pharmaceuticals by 9.4% in the 2nd quarter. New York State Common Retirement Fund now owns 286,453 shares of the biotechnology company’s stock valued at $4,841,000 after buying an additional 24,715 shares during the period. BlackRock Inc. raised its holdings in Momenta Pharmaceuticals by 7.1% in the 2nd quarter. BlackRock Inc. now owns 9,400,485 shares of the biotechnology company’s stock valued at $158,868,000 after buying an additional 626,415 shares during the period. Principal Financial Group Inc. raised its holdings in Momenta Pharmaceuticals by 12.0% in the 3rd quarter. Principal Financial Group Inc. now owns 606,700 shares of the biotechnology company’s stock valued at $11,224,000 after buying an additional 65,014 shares during the period. Rhumbline Advisers raised its holdings in Momenta Pharmaceuticals by 8.6% in the 2nd quarter. Rhumbline Advisers now owns 140,215 shares of the biotechnology company’s stock valued at $2,370,000 after buying an additional 11,128 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Momenta Pharmaceuticals in the 3rd quarter valued at about $1,141,000. Hedge funds and other institutional investors own 93.14% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Momenta Pharmaceuticals (NASDAQ:MNTA) Rating Increased to Buy at BidaskClub” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/02/05/momenta-pharmaceuticals-mnta-upgraded-to-buy-at-bidaskclub.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply